Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage

被引:6
|
作者
van Geest-Daalderop, JHH
Hutten, BA
Sturk, A
Levi, MM
机构
[1] Thrombosis Serv sHertogenbosch, NL-5223 GV Shertogenbosch, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Clin Chem, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
关键词
acenocoumarol; first INR and maintenance dosage; age and maintenance dosage; atrial fibrillation;
D O I
10.1023/B:THRO.0000011375.12034.62
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: This retrospective study was performed to develop a model to predict the maintenance dosage of the vitamin K antagonist acenocoumarol, based upon the first INR after a standard initial dosage regimen. Material and Methods: Outpatients with atrial fibrillation (n = 284) and initial regimens of 6-4 or 6-4-2 mg acenocoumarol on day 1, 2 and 3, respectively, were included. The maintenance dosage of the period 3 - 6 months after the instalment was related to the first INR after those standard initial dosage regimens, because in that period the INR was 76% of the time within the therapeutic range and therefore considered suitable to perform the analysis. Results: A clear relation was found between the first INR, the maintenance dosage and the age. A model that predicts the maintenance dosage immediately after the standard initial dosage and based on the first INR and adjusted for age, has been developed, according to the formula: required dosage = 5.03-1.65 * ln (first INR) - 0.01 * age. Conclusion: We have developed a formula to predict the maintenance dosage of acenocoumarol. With this formula it is possible to install this maintenance dosage and thus achieve oral anticoagulant therapy within the therapeutic range at an earlier stage. This will have to be shown in a prospective study.
引用
收藏
页码:197 / 203
页数:7
相关论文
共 44 条
  • [21] Triple therapy (aspirin, clopidogrel and oral anticoagulant) after percutaneous coronary intervention: another call for personalized medicine
    Tanrikulu, Azra
    Agirbasli, Mehmet
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2013, 13 (05) : 486 - 494
  • [22] 1-or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
    Valgimigli, Marco
    Spirito, Alessandro
    Sartori, Samantha
    Angiolillo, Dominick J.
    Vranckx, Pascal
    Hernandez, Jose M. de la Torre
    Krucoff, Mitchell W.
    Bangalore, Sripal
    Bhatt, Deepak L.
    Campo, Gianluca
    Cao, Davide
    Chehab, Bassem M.
    Choi, James W.
    Feng, Yihan
    Ge, Junbo
    Hermiller, James
    Kunadian, Vijay
    Lupo, Sydney
    Makkar, Raj R.
    Maksoud, Aziz
    Neumann, Franz-Josef
    Picon, Hector
    Saito, Shigeru
    Sardella, Gennaro
    Thiele, Holger
    Toelg, Ralph
    Varenne, Olivier
    Vogel, Birgit
    Zhou, Yujie
    Windecker, Stephan
    Mehran, Roxana
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (20) : 2498 - 2510
  • [23] Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: A systematic review and meta-analysis
    Proietti, Marco
    Romiti, Giulio Francesco
    Romanazzi, Imma
    Farcomeni, Alessio
    Staerk, Laila
    Nielsen, Peter Bronnum
    Lip, Gregory Y. H.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 261 : 84 - 91
  • [24] Evidence That D-Dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients With Atrial Fibrillation During Oral Anticoagulant Therapy
    Sadanaga, Tsuneaki
    Sadanaga, Motoaki
    Ogawa, Satoshi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (20) : 2226 - 2231
  • [25] Scoring System to Predict Major Bleeding Complications in Atrial Fibrillation Patients With Oral Anticoagulant After Drug-eluting Stent Implantation
    Kobayashi, Norihiro
    Ito, Yoshiaki
    Hirano, Keisuke
    Yamawaki, Masahiro
    Araki, Motoharu
    Muramatsu, Toshiya
    CIRCULATION, 2015, 132
  • [26] Soluble Monomer-Fibrinogen Complex Levels during Oral Anticoagulant Therapy Does Not Predict Subsequent Thromboembolic Events in Patients with Atrial Fibrillation
    Sadanaga, Tsuneaki
    Mitamura, Hideo
    CIRCULATION, 2012, 126 (21)
  • [27] Substantial differences in initiation of oral anticoagulant therapy and clinical outcome among non-valvular atrial fibrillation patients treated in inpatient and outpatient settings
    Mikkelsen, Anders Pretzmann
    Hansen, Morten Lock
    Olesen, Jonas Bjerring
    Hvidtfeldt, Morten Winther
    Karasoy, Deniz
    Husted, Steen
    Johnsen, Soren Paaske
    Brandes, Axel
    Gislason, Gunnar
    Torp-Pedersen, Christian
    Lamberts, Morten
    EUROPACE, 2016, 18 (04): : 492 - 500
  • [28] Soluble fibrin monomer complex levels during oral anticoagulant therapy do not predict subsequent thromboembolic events in patients with permanent atrial fibrillation
    Sadanaga, Tsuneaki
    Mitamura, Hideo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (01) : 578 - 580
  • [29] Single direct oral anticoagulant therapy in stable patients with atrial fibrillation beyond 1 year after coronary stent implantation
    Choi, Young
    Lee, Yunhee
    Kim, Sung-Hwan
    Kim, Sunhwa
    Kim, Ju Youn
    Kim, Tae-Seok
    Hwang, Youmi
    Kim, Ji-Hoon
    Jang, Sung-Won
    Lee, Man Young
    Oh, Yong-Seog
    HEART, 2022, 108 (04) : 285 - 291
  • [30] Criteria for the choice of anticoagulant therapy for the prevention of stroke in patients with atrial fibrillation early after the marketing of direct oral anticoagulants in Italy
    Marzona, I.
    Roncaglioni, M. C.
    Avanzini, F.
    Franzosi, M. G.
    Moia, M.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 41 : E12 - E14